Alan Lafley - Procter Gamble Executive Chairman and Member of Proxy Committee
| PG Stock | USD 156.96 1.01 0.65% |
Chairman
Mr. Alan G. Lafley is no longer Executive Chairman of the Board of the Company. effective June 30 2016. He was Chairman of the Board President Chief Executive Officer of The Procter Gamble Company. Mr. Lafley originally joined the Company in 1977 and held positions of increasing responsibility in the U.S. and internationally until he was elected President and Chief Executive Officer in 2000 a position he held until June 30 2009. On July 1 2002 Mr. Lafley was elected Chairman of the Board a position he held until January 2010. During the past five years in addition to his roles as a Company employee Mr. Lafley served as a consultant to the Company and as a member of the boards of directors of public companies Dell Inc. and General Electric Company. He no longer serves on these boards. Since his retirement from the Company he served as a Senior Advisor at Clayton Dubilier Rice LLC a private equity partnership and was appointed by President Obama to serve on The Presidents Council on Jobs and Competitiveness. Mr. Lafley consulted with a number of Fortune 50 companies on business and innovation strategy. He also advised on CEO succession and executive leadership development and coached experienced new and potential CEOs. He currently serves on the board of directors of Legendary Pictures LLC .
| Age | 67 |
| Address | One Procter & Gamble Plaza, Cincinnati, OH, United States, 45202 |
| Phone | 513 983 1100 |
| Web | https://www.pginvestor.com |
Procter Gamble Management Efficiency
The company has Return on Asset (ROA) of 0.1096 % which means that for every $100 of assets, it generated a profit of $0.1096. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.3178 %, which means that it produced $0.3178 on every 100 dollars invested by current stockholders. Procter Gamble's management efficiency ratios could be used to measure how well Procter Gamble manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.14. The current Return On Capital Employed is estimated to decrease to 0.20. At this time, Procter Gamble's Other Assets are most likely to increase significantly in the upcoming years. The Procter Gamble's current Asset Turnover is estimated to increase to 0.99, while Non Current Assets Total are projected to decrease to roughly 65.5 B.Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Nils Andersen | Unilever PLC ADR | 62 | |
| Michael Treschow | Unilever PLC ADR | 71 | |
| Thomas Falk | Kimberly Clark | 59 | |
| Marijn Dekkers | Unilever PLC ADR | 60 | |
| Michael Hsu | Kimberly Clark | 60 | |
| Matthew Shattock | The Clorox | 58 | |
| Youngme Moon | Unilever PLC ADR | 56 | |
| Benno Dorer | The Clorox | 55 | |
| Andrea Jung | Unilever PLC ADR | 61 | |
Management Performance
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.11 |
Procter Gamble Leadership Team
Elected by the shareholders, the Procter Gamble's board of directors comprises two types of representatives: Procter Gamble inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procter. The board's role is to monitor Procter Gamble's management team and ensure that shareholders' interests are well served. Procter Gamble's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procter Gamble's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Fish, Chief Research, Development and Innovation Officer | ||
| Craig Buchholz, Chief Communications Officer and Vice President – Communications, Personal Health Care and Oral Care | ||
| Matthew Janzaruk, Senior Officer | ||
| Mary FergusonMcHugh, Group President - Global Family Care and Global Brand Creation and Innovation, P&G Ventures | ||
| Kenneth Chenault, Independent Director | ||
| Debra Lee, Independent Director | ||
| Mindy Sherwood, President Global Walmart | ||
| Amy Chang, Independent Director | ||
| Nelson Peltz, Independent Director | ||
| Martin Riant, Group Pres and Advisor to the CEO | ||
| Hatsunori Kiriyama, President - Asia | ||
| Magesvaran Suranjan, President - Asia Pacific Selling and Market Operations | ||
| Kirti Singh, Chief Analytics and Insights Officer | ||
| Tarek Farahat, President - Latin America | ||
| Francis Blake, Independent Director | ||
| Thomas Finn, President - Personal Health Care | ||
| Mohamed Samir, President - India, Middle East and Africa (IMEA) Selling and Market Operations | ||
| Alexandra Keith, President - Global Hair Care and Beauty Sector | ||
| Susan DesmondHellmann, Independent Director | ||
| Valarie Sheppard, Controller and Treasurer and Executive Vice President - Company Transition Leader | ||
| Fama Francisco, Chief Executive Officer - Baby and Feminine Care | ||
| Loic Tassel, President - Europe | ||
| Margaret Whitman, Independent Director | ||
| Walter McNerney, Lead Independent Director | ||
| Terry Lundgren, Independent Director | ||
| Shelly McNamara, Senior Vice President of Human Resources | ||
| Angela Braly, Independent Director | ||
| Giovanni Ciserani, Group President of Global Fabric and Home Care and Global Baby and Feminine Care | ||
| M Grabowski, Chief Human Resource Officer | ||
| Victor Aguilar, Chief Research, Development and Innovation Officer | ||
| Damon Jones, Chief Officer | ||
| Javier Polit, Chief Information Officer | ||
| B Allen, Independent Director | ||
| James McNerney, Lead Independent Director | ||
| Ernesto Zedillo, Independent Director | ||
| Steven Bishop, Group President - Global Feminine and Family Care | ||
| Scott Cook, Independent Director | ||
| Henry Karamanoukian, President Go-to-Market, China and Hair Care, Greater China | ||
| Sundar Raman, President - Fabric Care, North America and P&G Professional, Global | ||
| Ernesto Leon, Independent Director | ||
| Susan Whaley, Chief Secretary | ||
| R Keith, President - Global Hair Care and Beauty Sector | ||
| Ma Francisco, Chief Executive Officer - Baby and Feminine Care | ||
| Yannis Skoufalos, Global Product Supply Officer | ||
| Linda ClementHolmes, CIO | ||
| Jennifer Davis, President - Feminine Care | ||
| John Chevalier, Director - Investor Relations | ||
| Juan Posada, President - Latin America Selling and Market Operations | ||
| Fatima Francisco, Feminine Baby | ||
| Alan Lafley, Executive Chairman and Member of Proxy Committee | ||
| Jeffrey Schomburger, Global Sales Officer | ||
| Monica Turner, Senior Vice President - Sales, North America | ||
| Vittorio Cretella, Chief Information Officer | ||
| Christine McCarthy, Independent Director | ||
| Patricia Woertz, Independent Director | ||
| Shailesh Jejurikar, Chief Operating Officer, Chief Executive Officer - Fabric and Home Care | ||
| Philip Duncan, Chief Design Officer | ||
| Andre Schulten, Chief Financial Officer | ||
| Marc Pritchard, Global Brand Building Officer | ||
| Markus Strobel, President - Skin & Personal Care | ||
| David Taylor, Chairman of the Board, President, Chief Executive Officer | ||
| Mark Biegger, Global Human Resources Officer | ||
| Joseph Jimenez, Lead Independent Director | ||
| Matthew Price, President - Greater China Selling and Market Operations | ||
| Julio Nemeth, President - Global Business Services | ||
| Laura Becker, President - Global Business Services | ||
| Deborah Majoras, Chief Legal Officer, Secretary | ||
| Jon Moeller, Vice Chairman of the Board, President, Chief Executive Officer | ||
| Patrice Louvet, Group President - Global Beauty | ||
| Charles Pierce, Group President - Global Grooming | ||
| Gary Coombe, President - Europe Selling and Market Operations | ||
| Carolyn Tastad, Group President - North America Selling and Market Operations | ||
| Ken Patel, Chief Counsel |
Procter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procter Gamble a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 392.7 B | ||||
| Shares Outstanding | 2.35 B | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 67.56 % | ||||
| Number Of Shares Shorted | 16.91 M | ||||
| Price To Earning | 25.21 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Procter Gamble using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procter Gamble. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in Procter Stock please use our How to Invest in Procter Gamble guide.Note that the Procter Gamble information on this page should be used as a complementary analysis to other Procter Gamble's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Procter Stock analysis
When running Procter Gamble's price analysis, check to measure Procter Gamble's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procter Gamble is operating at the current time. Most of Procter Gamble's value examination focuses on studying past and present price action to predict the probability of Procter Gamble's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procter Gamble's price. Additionally, you may evaluate how the addition of Procter Gamble to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Procter Gamble's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procter Gamble. If investors know Procter will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procter Gamble listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.11) | Dividend Share 3.735 | Earnings Share 5.97 | Revenue Per Share 35.567 | Quarterly Revenue Growth 0.032 |
The market value of Procter Gamble is measured differently than its book value, which is the value of Procter that is recorded on the company's balance sheet. Investors also form their own opinion of Procter Gamble's value that differs from its market value or its book value, called intrinsic value, which is Procter Gamble's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procter Gamble's market value can be influenced by many factors that don't directly affect Procter Gamble's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procter Gamble's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procter Gamble is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procter Gamble's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.